Overview

To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil

Status:
COMPLETED

Trial end date:
2024-05-24

Target enrollment:

Participant gender:

Summary

The main objective of the study will be to assess the efficacy and safety of Allisartan Isoproxil/sustained-release indapamide (240 mg/1.5 mg) in patients with mild to moderate essential hypertension uncontrolled after 4-week treatment with Allisartan Isoproxil (240 mg).

Phase:

PHASE3

Details

Lead Sponsor:

Shenzhen Salubris Pharmaceuticals Co., Ltd.

Treatments:

allisartan isoproxil